<p> Zika virus in the Americas: an HHS expert consultation to accelerate the development of countermeasures March 28-29, 2016 5601 Fishers Lane Conference Center Rockville, MD, USA</p><p>Goals of the Consultation:  Review the current information about the epidemiology and natural history (including potential link to microcephaly and other fetal malformations), clinical manifestations, modes of transmission and pathogenesis of Zika virus.</p><p> Identify critical gaps in knowledge, technologies, research infrastructure and regulatory oversight needed to address the current epidemic.</p><p> Discuss strategies to accelerate the development of vaccines, diagnostics, therapeutics and novel vector control methods.</p><p>This consultation is supported by NIAID, NICHD, ASPR/BARDA, CDC and FDA within the U.S. Department of Health and Human Services (NIAID/NIH/HHS).</p><p>MONDAY, 28 MARCH 2015, 12:00-18:30</p><p>11:00-12:00 Registration</p><p>OPENING REMARKS 12:00-12:30</p><p>Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health</p><p>Catherine Spong, M.D., Acting Director, National Institute of Child Health and Human Development, National Institutes of Health</p><p>Nicole Lurie, M.D., M.S.P.H., Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services</p><p>Beth P. Bell, M.D., M.P.H., Director, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention</p><p>Luciana Borio, M.D., Acting Chief Scientist, Food and Drug Administration</p><p>SESSION 1 Pathogenesis, Epidemiology, and Natural History Moderators: Name, Degree, Institution </p><p>12:30-12:50 Zika Virus Virology and transmission 1 Scott C. Weaver, Ph.D., University of Texas Medical Branch</p><p>12:50-13:10 Update of Zika Epidemic Lyle R. Petersen, M.D., Ph.D., Centers for Disease Control and Prevention</p><p>13:10-13:30 Epidemiology of Zika Infection and pregnancy in Brazil Federico Costa, Ph.D., Fiocruz, </p><p>13:30-13:30 Zika Infection with Neurological Outcome (Guillain-Barré Syndrome and Others) Jim J. Sejvar, M.D., Centers for Disease Control and Prevention</p><p>13:30-13:50 Clinical implications of Zika infection in pregnancy Peggy Honein, Ph.D., M.P.H., Centers for Disease Control and Prevention</p><p>13:50-14:05 Animal Models for Zika and Other Flaviviruses Pedro F.C. Vanconcelos, M.D., Ph.D., Instituto Evandro Chagas</p><p>14:05-14:20 Transmission Dynamics: Role of Asymptomatic Cases Thomas W. Scott, Ph.D., University of California, Davis</p><p>14:20-15:30 Pathogenesis, Epidemiology, and Natural History Panel Discussion  NICHD suggestions  Fernando Bozza, M.D., Ph.D., Fiocruz  Albert I. Ko, M.D., Yale School of Public Health  Ernesto T.A. Marquez, Jr., M.D., Ph.D., University of Pittsburgh  Duane J. Gubler, Sc.D., University of Hawaii, Mānoa  Erin Staples, M.D., Ph.D., Centers for Disease Control and Prevention  Sylvain Aldighieri, M.D., Pan American Health Organization </p><p>15:30-15:50 Break</p><p>SESSION 2 Vaccines Moderators: Name, Degrees, Institution</p><p>15:50-16:05 Flavivirus Vaccines: current status Thomas P. Monath, M.D., NewLink</p><p>16:05-16:20 Overview of Regulatory Considerations for Zika Vaccines Wellington Sun, M.D., FDA</p><p>16:20-17:50 Vaccines Panel Discussion  Barney Graham, M.D., Ph.D., National Institute of Allergy and Infectious Diseases  Stephen S. Whitehead, Ph.D., National Institute of Allergy and Infectious Diseases  Alexander R. Precioso, M.D., Ph.D., Instituto Butantan 2  Bruce Gellin, M.D., MPH, Director National Vaccine Program Office, HHS  Anvisa  SP and GSK</p><p>TUESDAY, 29 MARCH 2015, 08:30-17:00</p><p>SESSION 3 Diagnostics Moderators: Name, Degrees, Institution</p><p>08:30-08:50 Update on Existing Diagnostics for active infection and previous infections Robert S. Lanciotti, Ph.D., Centers for Disease Control and Prevention</p><p>08:50 -09:10 Blood Supply Monitoring Jay S. Epstein, M.D., Center for Biologics Evaluation and Research, U.S. Food and Drug Administration</p><p>09:10-09:25 Diagnostics under Development Rosemary Humes, Biomedical Advanced Research and Development Authority</p><p>09:25-09:40 Regulatory Considerations Uwe Scherf, Ph.D., U.S. Food and Drug Administration</p><p>09:40-10:40 Diagnostics Panel Discussion  Jorge L. Muñoz-Jordán, Ph.D., Centers for Disease Control and Prevention  Michael S. Diamond, M.D., Ph.D., Washington University in St Louis  Industry  Ted C. Pierson, Ph.D., National Institute of Allergy and Infectious Diseases</p><p>10:40-11:00 Break</p><p>SESSION 4 Therapeutics Moderators: Name, Degrees, Institution</p><p>11:00- 11:15 Flavivirus Therapeutics: current status Pei Yong Shi, Ph.D., University of Texas Medical Branch</p><p>3 11:15 -11:30 Overview of Regulatory Considerations for Therapeutics – Especially Use of Therapeutics in Pregnancy Christine Nguyen, M.D., U.S. Food and Drug Administration</p><p>11:30-12:00 Therapeutics Panel Discussion  Justin Julander, Ph.D., Utah State University  Pharma</p><p>12:00-13:00 Lunch</p><p>SESSION 5 Vector Control Strategies Moderators: Name, Degrees, Institution</p><p>13:00-13:20 Utility of Traditional Vector Control Methods/ Current Limitations William Black, Ph.D., Colorado State University </p><p>13:20-14:40 Novel Approaches to Vector Control: Wolbachia and RIDL Luciano A. Moreira, Ph.D., FIOCRUZ</p><p>14:40-15:40 Vector Control Panel Discussion  Stephen L. Dobson, Ph.D., University of Kentucky  José M.C. Ribeiro, M.D., Ph.D., National Institute of Allergy and Infectious Diseases  Carolina V. Barillas-Mury, M.D., Ph.D., National Institute of Allergy and Infectious Diseases  Roberto Barrera, Ph.D., Centers for Disease Control and Prevention  Industry</p><p>15:40-16:00 Break</p><p>SESSION 6 Future Steps and Conclusion: What should HHS do in the immediate and longer term to accelerate research and development of countermeasures? Moderators: Name, Degrees, Institution</p><p>17:00 Meeting adjourns</p><p>______</p><p>4</p>